Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): A combination phase 3 study

The Lancet

Volumn 386, Issue 10003, 2015, Pages 1537-1545

  Roth, David ^a   Nelson, David R ^b   Bruchfeld, Annette ^c   Liapakis, Annmarie ^d   Silva, Marcelo ^e   Monsour, Howard ^f   Martin, Paul ^a   Pol, Stanislas ^g   Londoño, Maria Carlota ^h   Hassanein, Tarek ⁱ   Zamor, Philippe J ^j   Zuckerman, Eli ^k   Wan, Shuyan ^l   Jackson, Beth ^l   Nguyen, Bach Yen ^l   Robertson, Michael ^l   Barr, Eliav ^l   Wahl, Janice ^l   Greaves, Wayne ^l  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d YALE UNIVERSITY   (United States)

^e UNIVERSIDAD AUSTRAL   (Argentina)

^f HOUSTON METHODIST HOSPITAL   (United States)

^g Institut Cochin   (France)

^h INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

ⁱ Southern California Research Center   (United States)

^j CAROLINAS MEDICAL CENTER   (United States)

^k CARMEL MEDICAL CENTER   (Israel)

^l MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; ELBASVIR; GRAZOPREVIR; HEMOGLOBIN; UREA; 2-(PYRROLIDIN-2-YL)-5-(2-(4-(5-(PYRROLIDIN-2-YL)-1H-IMIDAZOL-2-YL)PHENYL)BENZOFURAN-5-YL)-1H-IMIDAZOLE; BENZOFURAN DERIVATIVE; IMIDAZOLE DERIVATIVE; MK-5172; PROTEINASE INHIBITOR; QUINOXALINE DERIVATIVE; VIRUS RNA;

ADULT; AFRICAN AMERICAN; ALKALINE PHOSPHATASE BLOOD LEVEL; AORTA ANEURYSM; ARTICLE; BILIRUBIN BLOOD LEVEL; CARDIOMYOPATHY; CHRONIC HEPATITIS C; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HEART INFARCTION; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; UPPER GASTROINTESTINAL BLEEDING; UREA NITROGEN BLOOD LEVEL; AGED; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

AGED; BENZOFURANS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PROTEASE INHIBITORS; QUINOXALINES; RENAL INSUFFICIENCY, CHRONIC; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84947338288     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)00349-9     Document Type: Article

References (26)

1. F Fabrizi, V Dixit, P Messa Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat 19 2012 601 607
2. AA Butt, X Wang, LF Fried HCV infection and the incidence of CKD Am J Kidney Dis 57 2011 396 402
3. JI Tsui, E Vittinghoff, MG Shlipak et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease Arch Intern Med 167 2007 1271 1276
4. LA Noureddine, SA Usman, Z Yu, RN Moorthi, SM Moe Hepatitis C increases the risk of progression of chronic kidney disease in patients with glomerulonephritis Am J Nephrol 32 2010 311 316
5. BJG Pereira, TL Wright, CH Schmid, AS Levey The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation Transplantation 60 1995 799 805
6. C Legendre, V Garrigue, BC Le et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients Transplantation 65 1998 667 670
7. F Fabrizi, P Martin, V Dixit et al. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies Am J Transplant 5 2005 2433 2440
8. A Bruchfeld, H Wilczek, CG Elinder Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation Transplantation 78 2004 745 750
9. JM Cruzado, M Carrera, J Torras, JM Grinyo Hepatitis C virus infection and de novo glomerular lesions in renal allografts Am J Transplant 1 2001 171 178
10. V Summa, SW Ludmerer, JA McCauley et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants Antimicrob Agents Chemother 56 2012 4161 4167
11. M Sulkowski, C Hezode, J Gerstoft et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial Lancet 385 2015 1087 1097
12. E Lawitz, E Gane, B Pearlman et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial Lancet 385 2015 1075 1086
13. X Forns, SC Gordon, E Zuckerman et al. Grazoprevir/elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent J Hepatol 2015 10.1016/j.jhep.2015.04.009 published online April 17.
14. S Zeuzem, R Ghalib, KR Reddy et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial Ann Intern Med 163 2015 1 13
15. WW Yeh, L Caro, Z Guo et al. Pharmacokinetics of co-administered HCV protease inhibitor MK-5172 and NS5A inhibitor MK-8742 in volunteers with end-stage renal disease on hemodialysis or severe renal impairment not on hemodialysis Hepatology 60 suppl 4 2014 1940
16. AS Levey, J Coresh, T Greene et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate Ann Intern Med 145 2006 247 254
17. J Foucher, E Chanteloup, J Vergniol et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study Gut 55 2006 403 408
18. L Castera, X Forns, A Alberti Non-invasive evaluation of liver fibrosis using transient elastography J Hepatol 48 2008 835 847
19. J Boursier, V de Ledinghen, JP Zarski et al. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive Hepatology 55 2012 58 67
20. F Fabrizi, V Dixit, P Messa, P Martin Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials J Viral Hepat 15 2008 79 88
21. JG McHutchison, EJ Lawitz, ML Shiffman et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 2009 580 593
22. O Miettinen, M Nurminen Comparative analysis of two rates Stat Med 4 1985 213 226
23. S Mauss, D Hueppe, U Alshuth Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir Hepatology 59 2014 46 48
24. N Afdhal, S Zeuzem, P Kwo et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Engl J Med 370 2014 1889 1898
25. KV Kowdley, SC Gordon, KR Reddy et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis N Engl J Med 370 2014 1879 1888
26. CH Liu, CF Huang, CJ Liu et al. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial Ann Intern Med 159 2013 729 738